Citations

Clear

1792 citation(s) found for "Stephanie".

Measuring the Risk of Gluten Exposure: Development of the Gluten Exposure Risk Assessment in Pediatric Patients
Hale, Amy E. , Germone, Monique , Fahey, Lisa M. , Stahl, Marisa G. , Leonard, Maureen M. , Singh, Arunjot , Hajjat, Temara , Mallon, Daniel , Kerzner, Benny, Raber, Catherine , Badalyan, Vahe , Mehta, Pooja , Liu, Edwin , Shull, Mary , Absah, Imad , Ediger, Tracy , Jericho, Hilary , Khavari, Nasim, Jossen, Jackie , Wolf, Randi L. , Wong, Madison , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A. , RAISE-CD, Stahl, Marisa , Verma, Ritu , Jericho, Hilary , Wolf, Randi L , Regis, Stephanie , Weisbrod, Vanessa , Silvester, Jocelyn A , Mallon, Daniel , Lee, Dale Young , RAISE-CD

Mayo Clinic

American Journal of Gastroenterology | July 30, 2025 | Volume: 121 | Issue: 5 | Pages: 1251-1258

10.14309/ajg.0000000000003675 | PMID 40736693 Get It

INTRODUCTION: Treatment of celiac disease (CeD) requires a strict gluten-free diet (GFD). Adherence is difficult to assess and influenced by many factors. Identification of potential gluten exposures is essential, but no validated screening measures exist in pediatrics. The aim of this study was to develop and validate a measure screening for gluten exposure risk in pediatric patients with CeD. METHODS: The Gluten Exposure Risk Assessment (GERA) was developed in 3 phases. First, items were generated and refined by a modified Delphi process. Next, psychometrics, factor structure, and validity were examined in a sample of caregivers of pediatric patients younger than 18 years with CeD at 12 pediatric celiac centers. Finally, the final measure was tested on an independent sample population using confirmatory factor analysis and test-retest data. RESULTS: A total of 134 items were generated representing up to 6 domains, with 36 items selected for initial testing. Based on psychometrics and confirmatory factor analysis data from 484 caregivers, the final measure included a total of a single screening question and 9 validated items representing 2 domains (Home, Outside). Repeat testing on a separate sample (N = 369) confirmed factor structure and validity of the final measure (Comparative Fit Index = 0.96, Tucker–Lewis index = 0.95, root mean square error of approximation = 0.06). DISCUSSION: The GERA is a valid screening measure, completed by caregivers, for assessment of gluten exposure in children and adolescents with CeD following a GFD. GERA is a useful tool for evaluating the potential of risk of gluten exposure and potential need for intervention.
Sudden cardiac death secondary to acute aortic syndromes in young athletes in the United States
Petek, Bradley J. , Moulson, Nathaniel , Kliethermes‌, Stephanie , Maleszewski, Joseph J. , Drezner, Jonathan A. , Churchill, Timothy W. , Drezner, Jonathan A , Churchill, Timothy W , Kliethermes, Stephanie A , Baggish, Aaron L. , Delong, Randi , Kucera, Kristen L. , Harmon, Kimberly G.

Mayo Clinic

European Journal of Preventive Cardiology | July 30, 2025 | Volume: 33 | Issue: 8 | Pages: 1499-1501

10.1093/eurjpc/zwaf472 | PMID 40737489 Get It

Cognitive impairment in cerebral venous congestion: The need for improved assessment tools – a literature review
Hui, Ferdinand , Ghozy, Sherief , Amans, Matthew R. , Brinjikji, Waleed , Abdalkader, Mohamad , Yedavalli, Vivek , Chyung, Abraham SC, Siddiqui, Adnan H. , Hui, Ferdinand , Amans, Matthew , Siddiqui, Adnan H , Ghozy, Sherief , Yedavalli, Vivek S , Chyung, Abraham S.C., Mendes Pereira, Vitor , Lenck, Stéphanie , Hillis, Argye Elizabeth , Fargen, Kyle M

Mayo Clinic

Journal of NeuroInterventional Surgery | July 24, 2025 | Volume: 18 | Issue: 5 | Pages: 1401-1407

10.1136/jnis-2025-023392 | PMID 40707244 Get It

Objective Cognitive impairment is increasingly recognized in patients with cerebral venous congestion (CVC), yet the cognitive tools used are largely adapted from stroke and dementia research. This review examines current literature on cognitive function in CVC, including conditions such as cerebral venous sinus thrombosis (CVST), idiopathic intracranial hypertension (IIH), and dural arteriovenous fistulas (dAVFs). Special emphasis is placed on the limitations of common screening tools like the Montreal Cognitive Assessment (MoCA) and Mini-Mental State Examination (MMSE). Cognitive dysfunction—primarily affecting executive function, processing speed, and attention—is reported in up to 86% of CVC cases, yet only about 20% of studies use validated cognitive testing tools, most of which may lack sensitivity for CVC-specific deficits. Emerging techniques such as ocular motor testing and physiological markers show promise but require further validation. There is an urgent need for standardized, CVC-specific cognitive assessment protocols that reflect the unique pathophysiology of venous disorders. Future research should prioritize the development of targeted cognitive batteries and integrate objective physiological measures to enhance diagnostic accuracy.
Integration of Respiratory Care Experts and Emerging Technologies in Critical Care Simulation
Rausen, Michelle , Holst, Stephanie J. , Davis, Samantha , Rausen, Michelle S , Davis, Samantha P , Holst, Stephanie J.

Mayo Clinic

Journal of Intensive Care Medicine | July 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666251361064 | PMID 40697038 Get It

Respiratory Therapists (RTs) are indispensable members of the critical care team, yet their participation in the design and facilitation simulation-based training (SBT) remains significantly underrepresented. SBT provides healthcare professionals a risk-free environment to develop and maintain clinical and team skills, prepare for uncommon, high-risk scenarios and receive real-time feedback. This review examines critical contributions of RTs, encompassing their expertise in invasive procedures, mechanical ventilation management, and the burgeoning role of Advanced Practice Respiratory Therapists (APRTs). We explore the professional evolution of critical care and the parallel advancements in simulation technology, creating opportunities to enhance the training of all healthcare professionals. RTs possess unique clinical and technical skills ideally suited for the design and facilitation of critical care simulations. Their inclusion offers a powerful means to improve team training and patient outcomes. Integrating RTs into simulation programs has proven challenging. Resource limitations and staffing constraints require a multifaceted solution including dedicated full-time equivalents (FTEs) in simulation programs, specialized training in simulation pedagogy, and fostering robust interprofessional collaboration opportunities for RTs. Research demonstrating the return on investment (ROI) of integrating RTs into simulation is lacking, but remains crucial to securing the necessary resources and support. Research should focus on quantifiable improvements in trainee performance, team dynamics, and patient safety metrics. By fully integrating RTs into SBT, healthcare institutions can significantly enhance the quality of critical care training, fostering improved interprofessional teamwork, leading to better patient outcomes. This strategic investment in RT participation in SBT will yield substantial returns in improved healthcare delivery.
Prognostic Impact of Lymph Node Yield in a Phase III Clinical Trial (NRG/RTOG 9601) of Prostate Cancer Patients Treated With Salvage Radiation Following Prostatectomy
Chan, Emily , Pugh, Stephanie L. , Simko, Jeffry, Feng, Felix Y. , Shipley, William U. , Lukka, Himanshu, Bahary, Jean‐Paul, Pisansky, Thomas M. , Zeitzer, Kenneth L. , Gore, Elizabeth , Balogh, Alexander G., Lovett, R.D., Wong, Anthony , Dess, Robert T. , McGinnis, L.S., Kuettel, Michael, DeMora, Luda, Dess, Robert T , Bahary, Jean-Paul , Efstathiou, Jason A. , Rosenthal, Seth A. , DeMora, Luda, Sandler, Howard M.

Mayo Clinic

The Prostate | July 21, 2025 | Volume: 85 | Issue: 14 | Pages: 1315-1322

10.1002/pros.70018 | PMID 40686005 Get It

ABSTRACTBackgroundWe aim to evaluate whether increased lymph node yield at prostatectomy (RP) is associated with improved outcomes in NRG/RTOG 9601, a randomized clinical trial of men who underwent either radiation (RT) alone or RT + bicalutamide for PSA elevation following RP for pT2/T3 prostate cancer.MethodsWe reviewed available pathology reports for patients in NRG/RTOG 9601 to determine the nodal count at RP. Cox proportional hazards models were used to assess effect of lymph nodes yield, arm (RT alone or RT + bicalutamide), Gleason score, positive margins, and seminal vesicle invasion on the following endpoints: times to local and distant failure and overall and disease‐specific survival.ResultsOf 760 patients, 552 (73%, 276 in each arm) had complete data available. Median node count in the entire cohort was 6 (range: 0–33, IQR: 3–9). There were no significant differences between arms in terms of patient demographic or clinical characteristics, including total lymph nodes removed in either arm. There was no significant association between total lymph nodes and overall or disease‐specific survival with both arms combined and when adjusting for arm. Notably, interaction analysis revealed that in seminal vesicle invasion, there was a significant association between lymph node yield and OS and DSS (HR = 0.91, 95% CI: 0.83–0.99, p = 0.034; HR = 0.87, 95% CI: 0.77–0.99, p = 0.029, respectively).ConclusionsAlthough lymph node yield in NRG/RTOG 9601 did not show association with adverse outcomes in the entire cohort or either arm alone, there was significant association between lymph node yield and adverse outcomes when seminal vesicle invasion was present. The therapeutic benefit of extensive lymph node dissection remains uncertain but could be more relevant in higher risk patients.
MRI characteristics during attack and remission distinguish patients with MOG antibody-associated disease from multiple sclerosis
Cacciaguerra, Laura , Tajfirouz, Deena , Redenbaugh, Vyanka , Krecke, Karl N. , Thakolwiboon, Smathorn , Madhavan, Ajay A. , Tillema, Jan-Mendelt , López‐Chiriboga, A. Sebastian , Chen, John J. , Syc-Mazurek, Stephanie B , Cacciaguerra, Laura , Tajfirouz, Deena , Thakolwiboon, Smathorn , Madhavan, Ajay A , Valencia Sanchez, Cristina , Sechi, Elia , Pittock, S J , Flanagan, E P , Chen, John J , Syc‐Mazurek, Stephanie B. , Dinoto, Alessandro , Tillema, Jan‐Mendelt , Valencia-Sánchez, Cristina , Sechi, Elia , Pittock, Sean J. , Flanagan, Eoin P.

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | July 20, 2025 | Volume: No volume available | Issue: No issue available | Pages: jnnp-2025-336684

10.1136/jnnp-2025-336684 | PMID 40685157 Get It

Background Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) and multiple sclerosis (MS) have both overlapping and distinct MRI lesion features, which vary with imaging timing. This study identified distinguishing MRI characteristics using paired MRIs at clinical attack and remission. Methods We retrospectively identified Mayo Clinic patients with MOGAD and MS that: (1) fulfilled respective diagnostic criteria; (2) had paired attack (≤30 days) and remission MRI scans (≥12 months) without interval attacks. MRIs were compared between groups for key features. Results We included 43 patients with MOGAD (median age 31 years (range, 3–67); 63% female) and 49 patients with MS (median age 39 years (range, 17–65); 65% female). Resolution of at least one T2-lesion differentiated MOGAD from MS (sensitivity, (95% CI 77% to 100%), specificity, (95% CI 86% to 99%); Youden’s index (YI)=0.90). Resolution of at least two T2-lesions indicated MOGAD (sensitivity 62% (95% CI 41% to 79%); specificity, 100% (95% CI 94% to 100%); YI=0.62). MOGAD patients were more likely to have normal MRI scans at follow-up compared with MS (brain 14/44 (32%) vs 0/60 (0%), p<0.001; spine 21/27 (78%) vs 7/36 (19%), p<0.001). In addition, the presence of T1-hypointense, ovoid periventricular T2, and enhancing lesions were more common in MS versus MOGAD at attack and remission and in the spine, longitudinally extensive T2 lesions were more common in MOGAD attacks (8/27 (30%)). Conclusion Paired MRI at attack and remission revealed distinctive characteristics of MOGAD and MS, with greater diagnostic value at remission driven by the discriminating power of T2-lesion resolution. In MOGAD patients with initial parenchymal involvement, a 1-year follow-up MRI may aid diagnosis and serve as a new baseline.
Early Findings from the Multicenter RAPID Consortium on Papillary Craniopharyngiomas
Catalino, Michael P. , Pham, D. T. , Couldwell, William T. , Evans, James J., Callopy, Calen, Pacione, Donato , Suryadevara, Carter M. , Silverstein, Julie , Gardner, Paul A. , Barkhoudarian, Garni , Miranda, Juan Carlos Fernández, Benjamin, Carolina , Kshettry, Varun R. , Zada, Gabriel , Zwagerman, Nathan T. , Cheok, Stephanie , Wu, Kyle C., Little, Andrew S. , Karsy, Michael , Couldwell, William T , Chicoine, Michael , Kshettry, Varun R , Van Gompel, Jamie J , Palit, Sandhya R. , Karsy, Michael , Pham, Duy, Rennert, Robert C , Kim, Won Bae , Kim, Albert , Gompel, Jamie J. Van , Prevedello, Daniel M. , Mamelak, Adam N. , Pacult, Mark A.

Mayo Clinic

Journal of Neurological Surgery Part B: Skull Base | July 18, 2025 | Volume: 87 | Issue: 04 | Pages: 406-413

10.1055/a-2646-2339 | PMID 42404182 Get It

Abstract Craniopharyngiomas are rare parasellar tumors, and papillary craniopharyngiomas (PCPs) represent 8 to 20% of cases. Interim analysis of retrospective data collected from the Registry of Adenomas of the Pituitary and Related Disorders (RAPID). Fourteen U.S.-based academic skull base centers between 2011 and 2023. Patients with PCPs. Demographic, imaging, surgical, and outcome variables. Ninety-nine patients with PCPs were included. The mean age was 51.8 ± 14.7, and 57.6% were male. Most tumors showed mixed cystic/solid components (67.5%), were transinfundibular (50.0%), and were treated with an endoscopic endonasal approach (74.5%), with 51.1% demonstrating gross total resection (GTR). Pituitary stalk was preserved in 51.9%. Permanent arginine vasopressin deficiency was seen in 67.1% and was associated with pituitary stalk sacrifice (p = 0.003). Cerebrospinal fluid leak was the most common nonendocrine postsurgical, 30-day complication (9.1%), reason for return to the operating room (3.1%), and reason for 90-day readmission (8.1%). Most patients (63.9%) received no adjuvant therapy; GTR was associated with decreased radiotherapy use (p = 0.0001). BRAFV600E mutation was detected in 64/69 tumors tested, although only one patient was treated with a BRAF inhibitor. A mean follow-up of 12.3 ± 14.6 months was seen for the group. RAPID consortium enabled the largest real-world clinical information dataset for PCPs. Early findings support that GTR and stalk preservation are important to outcomes. Iterative analysis and discussion of data led to the generation of a framework for future studies to fully leverage the capabilities of multicenter registries.
Validation of the Perimenopause Symptom Scale (Peri-SS) for Digital Self-Assessment: Psychometric Evaluation Among U.S. Women Aged 35 to 59 years
Xu, Yihan , Ilyich, Irina, Prentice, Carley , Martin, Yella , Cunningham, Adam , Shufelt, Chrisandra , Faubion, Stephanie S. , Zhaunova, Liudmila , Shufelt, Chrisandra L , Faubion, Stephanie S , Cunningham, Adam C , Zhaunova, Liudmila , Hewings-Martin, Yella , Xu, Yihan

Mayo Clinic

No container title available | July 18, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.07.16.25331654 Get It

Abstract Objective Perimenopause is an under-recognized transition poorly measured by existing tools, which often overlook symptoms characteristic of this phase. To address this, we developed and validated the Perimenopause Symptom Scale (Peri-SS): a concise, phase-specific, psychometrically robust instrument for digital self-assessment and research use among U.S. women aged 35-59 who self-reported in perimenopause. Methods We conducted a longitudinal validation study with 1,255 U.S. women aged 35-59 (633 identified as perimenopausal) recruited via Prolific. Participants completed the Peri-SS, Menopause Rating Scale (MRS), and EuroQol 5-Dimension, 5-Level (EQ-5D-5L) at baseline and 7-14 days later. Following COSMIN guidelines, we assessed structural validity, internal consistency, test-retest reliability, criterion and construct validity, and responsiveness to change. Results The Peri-SS demonstrated strong psychometric performance. Confirmatory factor analysis confirmed a four-domain structure (vasomotor, psychological, sexual, physical), with excellent model fit (CFI = 0.932, RMSEA = 0.069). Internal consistency was excellent (α = 0.90 overall; domain range 0.73-0.86), and test-retest reliability was high (ICC = 0.82). Criterion validity was strong, with Peri-SS scores highly correlated with MRS (r = 0.88). Construct validity was supported through moderate correlations with EQ-5D-5L utilities (ρ = -0.50) and effective discrimination between groups by age, menopausal status, and hormone therapy use. The scale was also responsive to symptom changes over time (η² = 0.277). Conclusions The Peri-SS is a reliable, valid, responsive tool for assessing perimenopausal symptom burden. Its concise format and strong psychometric performance make it well-suited for research, clinical care, and digital health applications. Two sentence summary The Perimenopause Symptom Scale (Peri-SS) is a novel 16-item instrument developed to measure symptom burden during perimenopause across four domains. In a validation study among U.S. women aged 35-59 years, the Peri-SS demonstrated strong reliability, validity, and responsiveness, supporting its use in research, clinical care, and digital health settings.
Personalized care for patients with EGFR‐mutant nonsmall cell lung cancer: Navigating early to advanced disease management
Borgeaud, Maxime , Olivier, Timothée , Bar, Jair , Saw, Stephanie P.L. , Parikh, Kaushal , Banna, Giuseppe Luigi , Vito, Claudio De , Feldman, Jill , Le, Xiuning , Addeo, Alfredo , Saw, Stephanie Pei Li , De Vito, Claudio , Addeo, Alfredo , Olivier, Timothée , Feldman, Jill

Mayo Clinic

CA: A Cancer Journal for Clinicians | July 17, 2025 | Volume: 75 | Issue: 5 | Pages: 387-409

10.3322/caac.70024 | PMID 40673977 Get It

AbstractThe discovery of activating mutations in the epidermal growth factor receptor (EGFR) gene has revolutionized the management of lung cancer, enabling the development of targeted tyrosine kinase inhibitors (TKIs). These therapies offer improved survival and reduced side effects compared with conventional treatments. Recent advancements have significantly reshaped the treatment paradigm for EGFR‐mutant non‐small cell lung cancer. TKIs are now incorporated into the management of early stage and locally advanced disease, and phase 3 trials have explored combination strategies in metastatic settings. Although these intensified approaches improve progression‐free survival, they come with increased toxicity and higher costs, underscoring the need for precise patient selection to maximize benefit. Emerging data on biomarkers, such as co‐mutations and circulating tumor DNA, show promise for refining treatment decisions. In addition, significant progress in understanding resistance mechanisms to EGFR TKIs has broadened therapeutic options. This review provides a comprehensive overview of the current landscape of EGFR‐mutant nonsmall cell lung cancer, highlighting recent breakthroughs and discussing strategies to optimize treatment based on the latest evidence.
Clinical evaluation of adults undergoing elective surgery utilizing intraoperative incisional wound irrigation (CLEAN Wound): protocol for a randomised controlled trial
Roke, Rachel , Lillie, Erin , Daneman, Nick , Mason, Stephanie, Jiang, Yidi , Shiroky, Jonah , Puran, Sudarshani, Smith, David E. , Khalil, Jad Abou, Kayssi, Ahmed , Pinchuk, Brian, Apte, Sameer , Lamb, Tyler , Ma, Grace , Vogt, Kelly, Leslie, Kenneth , Mutabdzic, Dorotea, Gómez, David , Ladha, Karim S. , Bennett, Sean, Ullah, Shahnoor M, Holland, Jessica, Smith, Andrew J., Calderone, Michael, Herriott, Judith, Voltan, Ed, Sloan, B., Mazer, C. David , Kennedy, Erin, Aarts, Mary-Anne, Karanicolas, Paul J. , Kayssi, Ahmed , Apte, Sameer S , Lamb, Tyler , Delisle, Megan , Muaddi, Hala , Fergusson, Dean A , Marshall, John C. , Karanicolas, Paul Jack , Tomlinson, George , Serrano, Pablo E , Vogt, Kelly, Tsang, Melanie E. , Ullah, Shahnoor M, Nathens, Avery B.

Mayo Clinic

BMJ Open | July 17, 2025 | Volume: 15 | Issue: 7 | Pages: e104375

10.1136/bmjopen-2025-104375 | PMID 40675632 Get It

Introduction In moderate to high-risk surgical procedures, 15–25% of patients develop a postoperative surgical site infection. Intraoperative incisional wound irrigation has the potential to reduce surgical site infections, and additional randomised controlled trials are required to provide evidence of effectiveness. Methods and analysis This protocol describes a pragmatic, adaptive, participant and adjudicator-blinded trial at 13 sites in Canada in up to 2500 participants. Participants planned for surgery with an abdominal or groin incision, who are eligible and provide verbal consent through an integrated consent model, are randomised to receive intraoperative incisional wound irrigation with povidone-iodine, saline or no irrigation. The primary outcome is surgical site infection within 30 days postoperatively. Secondary outcomes include quality of life measured 30 days postoperatively and morbidity, mortality and healthcare utilisation within 90 days postoperatively. Ethics and dissemination This trial has been approved by the research ethics board at the participating centres and stopped enrolling participants on May 23, 2025. All participants will provide verbal consent. Results will be disseminated via presentation at conferences, publication and posted on clinicaltrials.gov. Trial registration number The study is registered with http://clinicaltrial.gov ( NCT04548661 ; 14 September 2020).